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Abstract Advances in the study of hematopoietic cell
maturation have paved the way to a deeper understanding
the stem and progenitor cellular hierarchy in the mammary
gland. The mammary epithelium, unlike the hematopoietic
cellular hierarchy, sits in a complex niche where commu-
nication between epithelial cells and signals from the
systemic hormonal milieu, as well as from extra-cellular
matrix, influence cell fate decisions and contribute to tissue
homeostasis. We review the discovery, definition and
regulation of the mammary cellular hierarchy and we
describe the development of the concepts that have guided
our investigations. We outline recent advances in in vivo
lineage tracing that is now challenging many of our
assumptions regarding the behavior of mammary stem
cells, and we show how understanding these cellular lin-
eages has altered our view of breast cancer.
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SCA-1 Stem cell antigen
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Stat5A Signal transducer and activator of
transcription 5A
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Tgf-b Transforming growth factor beta
Tnfsf11 Tumor necrosis factor ligand superfamily
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Discovery of mammary stem and progenitor cells
Experimental mammary biology leapt ahead with the pio-
neering work of DeOme and colleagues [1]. They
demonstrated that small epithelial fragments of normal or
hyperplastic mouse mammary epithelium gave rise to
morphologically similar outgrowths when transplanted into
de-epithelialized mammary fat pads. Importantly, these
outgrowths produced secondary outgrowths when trans-
planted, confirming that the mammary epithelium contains
cells with self-renewing potential, multipotency and cell-
autonomous actions, all the characteristics of stem cells [2].
This transplantation technique is one of the most useful
methods in mammary biology, used to demonstrate repop-
ulating capacity and self-renewing potential of mammary
cells [3, 4], for defining the cell-autonomous role of
molecular regulators of cell specification and for isolating
their effects from systemic confounders in a variety of
applications [5–9]. Using this technique, Smith reported
that transplantation of dissociated mammary epithelial cells
at limiting dilution revealed three types of outgrowths;
lobules, ducts or complete glands. [10]. The ability of serial
transplants to produce either lobules or ducts decayed
independently of each other, suggesting that this was not
just a property of diluted cells [11]. The observations of
outgrowths forming only lobules or ducts pointed to the
existence of founding cells committed to these fates, but
what was not clear was whether these lineage-restricted
progenitors cooperated to establish the complete mammary
outgrowth, or whether a ‘master mammary stem cell’ could
give rise to the entire mammary epithelium [12]. Varmus,
Cardiff and colleagues [13, 14] observed that the
mouse mammary tumor virus (MMTV) inserts its proviral
DNA randomly into the genome of a newly infected pup.
This observation provided an ingenious way to track
mammary epithelial cells. Exploiting the integration of
MMTV to fate-map cells, Kordon and Smith [12] used
MMTV to investigate the clonal origins of the mammary
gland. These experiments were one of the earliest uses of
lineage tracing. CzechII mice were infected with MMTV,
and mammary tissue was serially transplanted into unin-
fected hosts. Subsequent genomic Southern blot analysis
revealed identical viral insertion sites in primary and sec-
ondary outgrowths. These experiments demonstrated that
the mammary epithelium is derived from a multipotent and
self-renewing mammary stem cell. Subsequent estimates of
the capacity of mammary epithelial stem cells to undergo
symmetric cell divisions led to the conclusion that a single
mammary stem cell could give rise to an entire functional
mammary gland [12]. Similar conclusions were drawn
regarding clonally dominant populations in the human
breast, where identical X-chromosome inactivation patterns
can be observed in contiguous clonal areas of both luminal
and myoepithelial cells [15]. Transplantation showed that
mammary stem cells were located sporadically throughout
the mammary epithelium and concentrated in the cap cells
of the terminal end buds. These stem cells were present in
the mammary gland at various stages throughout develop-
ment and were long lived. They also maintained their
repopulating capacity throughout the lifespan of a rodent, as
they were functionally identical whether isolated from a
young or old animal [16], or as transplants or isolated cells
from age and parity-matched animals [17]. These experi-
ments established the foundations for our current
understanding [18, 19] of the cellular hierarchy of the
mammary gland, that a multipotent mammary stem cell can
give rise to all the functional-differentiated cells in the
mammary gland, that maintenance of tissue homeostasis by
localized stem cells produced clonal regions within the
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mammary epithelial tree, and that progenitor cell popula-
tions restricted to lobule or ductal development existed.
Isolation of mammary stem cell and progenitor cells
First attempts to visualize the mammary stem cell were
made by histological investigation, where they were pos-
tulated to be morphologically distinct, characterized by pale
staining nucleus and cytoplasm containing few organelles
(small light cells). These cells were absent in senescent
glands, pointing to their regenerative capacity [20, 21], and
similar cells with stem cell properties were seen in human
tissues when cultured in 3D culture systems [22]. The
extensively studied differentiation hierarchy of the hema-
topoietic system, and the well-developed flow cytometric
methods, provided an alternative experimental and organi-
zational paradigm to dissect and describe the cellular
hierarchy in the mammary gland [23]. For review, see [24,
25]. Mammary biologists implemented similar strategies
combined with intricate tissue dissociation and more gentle
antibody-based flow cytometry techniques, to delineate the
mammary cellular hierarchy and understand how it is reg-
ulated [26]. Some caveats are immediately obvious. Tissues
provide positional cues to stem and progenitor cells, the
stem cell niche that is absent in the blood. Loss of cellular
context during tissue disaggregation, and its random
replacement during transplantation, may alter subsequent
stem cell behavior. Other caveats are less obvious and more
insidious, such as the assumption that the stem cell is an
entity rather than an activity, and of a simple, Waddington-
like cellular hierarchy, as the paradigm for solid tissues.
Some of the earliest experiments using tissue disaggre-
gation and fluorescence-activated cell sorting (FACS) to
isolate different cellular populations in the mammary gland
suggested that both the myoepithelial and luminal epithe-
lial fractions contain populations with heterogeneous
cellular identities [27, 28]. In 1991, an antibody to epi-
thelial membrane antigen (EMA/25.5/MUC1) was
developed that recognized only luminal epithelial cells of
the mammary gland throughout development [28]. Its use
in conjunction with an antibody against common lympho-
blastic leukemia antigen (CALLA/NEP/gp100), which in
the mammary gland stained the basally located cells of the
myoepithelial cell layer, allowed the mammary epithelium
to be fractionated into its basal and luminal components
[28]. Later, Dundas and colleagues [27] used the same
markers to characterize these two populations in vitro.
Curiously, two different basal cytokeratin 14-positive
(CK14?) clones were derived from the CALLA? fraction,
a highly proliferative and predominantly smooth muscle
actin negative (SMA-) clone and a slowly growing
(SMA?) clone. The EMA? fraction gave rise to three
clones, two slow-growing clones expressing the luminal
markers cytokeratin 7/18/19 (CK7?, CK18? and CK19?)
and a third that gave rise to a fast-growing heterogeneous
population of basal (CK14?), luminal (CK18?) cells and
bi-lineage (CK14?/CK18?) cells. All clones could be iso-
lated from both the ductal and alveolar compartments
although their proportions differed depending on origin.
The problem with these early studies is that these cell
fractions were heavily contaminated with unknown cells
derived from the stroma. Smalley and colleagues were
aware of this issue and attempted to purify epithelial or-
ganoids away from contaminating stromal cells by short-
term plating of collagenase-digested tissues [29]. Stromal
cells adhered to the plate quickly leaving the unattached
organoids in suspension to be isolated and further digested
and fractionated by FACS. In this study, luminal cells were
isolated using an antibody against mouse milk fat globule
membrane antigen (MFGM/33A10) and myoepithelial
cells isolated using an antibody to myoepithelial/basal cells
(JB6). When cloned in vitro, JB6? basal/myoepithelial
cells gave rise to a single slow-growing clone and MFGM-
positive luminal epithelial cells gave rise to three different
phenotypes, although the myoepithelial (CK14?/SMA?)
and luminal (CK8, CK18 and CK19) identity of these
clones was not stable in culture. This issue was solved
when each population was cultured in 3D on extracellular
matrix (ECM) [30]. Greater than 90 % of all JB6?, myo-
epithelial clones expressed the basal marker CK14 and
most were also positive for alpha SMA. Grown on ECM,
the MFGM? luminal epithelial cells generated two types of
clones, one with flattened morphology and the other
rounded that formed complex acinar colonies that invaded
the ECM. The flattened clones were characterized by two
colony types, a monolayer (Type I, 90 % of flat clones) that
expressed both basal and luminal markers (CK14 and
CK18) and a multilayered colony (Type II, 10 % of flat
clones), which consisted of a CK14?/CK18- basal layer
intimately in contact with the ECM that surrounded a
cuboidal layer with a mixture of luminal CK14-/CK18?
and bi-lineage cells. The outgrowths that grew out from
MFGM, and only in areas where the ECM was thickest,
were composed of a central/inner cell mass of luminal
CK14-/CK18? cells surrounded by an outer layer of
double stained bi-lineage and presumably undifferentiated
CK14?/CK18? cells. Interestingly, luminal-derived clones
on ECM were also positive for CK19 and expressed b-
casein when grown in lactation medium. These data sug-
gested that the luminal compartment purified using MGFM
contains multipotent cells capable of giving rise to both
undifferentiated basal cells and functionally competent
luminal cells. A human breast progenitor cell separated on
the basis of the expression of the MAM-6/sialomucin?
(luminal cells) and CALLA? (myoepithelial cells) was
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discovered using magnetic bead separation [31, 32]. In a
specially formulated medium, a small proportion of the
MAM-6? cells gave rise to a population of morphologi-
cally distinct CALLA?, SMA alpha? and vimentin?
myoepithelial cells that had lost expression of CK18 and
CK19. Hence, it was postulated that all progenitor cell
activity resides in the luminal compartment in the human
breast [32]. The importance of the luminal origins of this
progenitor cell will become apparent below. As significant
heterogeneity in morphology and function was still
apparent in the myoepithelial and luminal compartments
separated by markers mentioned above, the search con-
tinued for more specific markers of mammary stem and
progenitor cells.
Expression of the ATP-binding cassette family of mem-
brane transporters, notably the expression of Breast Cancer
Resistance Protein 1 (Brcp1/Abcg2) is greatest in primitive
hematopoietic stem cells and mediates rhodamine 123 and
Hoechst 33342 dye efflux [33]. This population is observed
as a small negative side population by FACS [34, 35] that can
be masked by pre-treatment with voltage-dependent calcium
channel blocker Verapamil. Hoechst-33342 dye efflux was
explored as a potential marker of multipotent mammary stem
cell in mouse and human mammary glands [36, 37]. Side
population (SP) cells, which excluded Hoechst 33342, were
enriched for stem cell antigen-1 (Sca-1, 80 % of SP [37]), an
additional marker of stemness in the hematopoietic system
[33, 38]. Transplantation of less than 4,000 SP cells resulted
in complete mammary outgrowths containing both ductal
and alveolar populations [37], a significant improvement
from unsorted mammary epithelium [10], and suggested that
the SP was enriched for mammary stem cells [10]. Similar
enrichment of undifferentiated and multipotent mammary
stem cells was observed for the SP isolated from the human
breast [36]. Interestingly, the SP expressed lower levels of
cytokeratins and higher levels of vimentin than the non-side
population cells and was further enriched for catalytic sub-
unit of telomerase (hTERT) [36], characteristics of primitive
stem cells.
Compared to cells enriched from the Hoechst-33342 SP,
as few as 1000 Sca-1? cells could give rise to partial or
complete mammary outgrowths and suggested that Sca-1 is
an improved marker of mammary stem cells. The location
of these cells was examined in a Sca-1?/GFP reporter
mouse. Sca-1 positive cells were found scattered through-
out the mammary epithelium, but the greatest number of
Sca-1 positive cells were found at the distal tips of
extending ducts [37], a localization for stem cells that been
suggested before [12]. Interestingly, Sca-1? cells segre-
gated with progesterone receptor (PR) expression, retained
label (BrdU) over long periods and possessed an undif-
ferentiated molecular phenotype [37]. These data suggest
that the Sca-1? mammary epithelial population is enriched
for undifferentiated, long-lived and multipotent mammary
stem cells and that Sca-1 appeared to be a better marker of
mammary stem cells than dye efflux properties.
Unfortunately, 20 % of the Hoechst-33342 positive
population also expressed Sca-1 [37], as did stromal cells
[39], hence better markers were needed to enrich for and
understand the biology of mammary stem cells. Following
on studies by Al Hajj and colleagues that demonstrated the
utility of marker for CD24 (Heat stable antigen/HAS/BA-
1) in isolating tumorigenic cells from breast cancers (to be
discussed in detail below) [40], the Smalley laboratory then
investigated the utility of CD24 in fractionating the
mammary epithelium [41]. CD45? leukocytes were
excluded from dissociated mammary tissue, and the
remaining cells sorted into three populations based on
CD24 expression: negative (CD24-), low (CD24lo) and
high (CD24hi) expression. The CD24hi population almost
exclusively expressed the luminal markers CK8/CK18 and
had restricted mammary reconstitution potential in limiting
dilution transplantation assays. Ninety-four percent of the
CD24lo population expressed the basal/myoepithelial
marker CK14 and were highly enriched for mammary stem
cells. Further fractionation of these compartments came
from the addition of an antibody against the glycoprotein
Prominin-1 (CD133/AC133), a marker for hematopoietic
progenitor cells [42]. Prominin-1 and Sca1 displayed
almost identical flow cytometric-staining patterns within
the CD24? epithelial compartment, however unlike Sca-1,
Prominin-1 was restricted to the CD24? epithelial com-
partment. Interestingly, expression for Prominin-1 could
fractionate CD24hi cells into two compartments; a CD24?/
Prominin-1? hormone-sensing compartment expressing
high levels of estrogen receptor (ER), PR and Prlr and
Cited-1; and a CD24?/Prominin-1- hormone receptor-
negative secretory progenitor cell enriched for in vitro
colony-forming ability and capable of milk production
[43]. Appropriate steroid hormone receptor patterning and
paracrine signaling from hormone-sensing cells was
already recognized as a key feature of normal mammary
gland establishment and function [44–46]. CD24lo stem
cells were predominantly basal cells and did not express
the steroid hormone receptors, hence these data demon-
strated that most of the stem and progenitor activity in the
mammary gland predominantly resides in the steroid
receptor-negative basal compartment, and these cells are
probably responsive to growth and differentiation signals
from the hormone-sensing compartment.
It was clear from these studies that no one marker could
be used to purify cell types in the mammary gland. Great
advances in the understanding of the breast and mammary
cellular hierarchy came from using a combination of dif-
ferent markers to fractionate subsets of the epithelium [3, 4,
47, 48]. Antibodies directed against the luminal antigens
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EpCAM (ESA) and MUC1 (Mucin-1/EMA) and the basal
antigen CALLA were used in combination to fractionate
the human breast epithelium and examine their colony-
forming ability in in vitro [47]. EpCAM had previously
been shown to be a cell surface marker of breast and
colorectal carcinomas [49]. Three different colony-forming
populations were discovered in these 3D culture systems;
the first, a MUC?CALLA-/EpCAM? population that
produced CK8/CK18- and CK19-positive alveolar colonies
in ECM; the second, a MUC-/CALLA?/EpCAM- popu-
lation that produced colonies of exclusively myoepithelial
cells expressing CK14; and lastly, a MUC- to ±/CALLA±/
EpCAM? bi-lineage population that gave rise to large
branched colonies of both myoepithelial (CK14?) and
luminal (CK8/18? and CK19?) cells [47]. Hence it was
postulated that two progenitor populations maintained
cellular homeostasis in the human breast; a bipotent pro-
genitor (MUC- to ±/CALLA±/EpCAM?) that could give
rise to both luminal and myoepithelial cells and a luminal
(or alveolar) restricted progenitor (MUC?/CALLA-/Ep-
CAM?) that could give rise alveolar colonies. As ESA/
EpCAM expression was predominantly found within the
luminal layer of human breast tissue, these results suggest
that this bipotent progenitor may be luminal in origin.
Adding the marker for CD49f (integrin alpha 6/VLA) could
further fractionate these human progenitor populations
[48]. EpCAM?/CD49f?/MUC1? sorted cells produced
luminal (alveolar) restricted colonies expressing CK8/18
and CK19, akin to the MUC?/CALLA-/EpCAM? dis-
covered above. The bipotent progenitors were found in a
population similarly characterized by EpCAM?/CD49f?,
but had lower expression of MUC, higher expression of
CALLA and showed rhodamine 123 efflux properties.
Cells derived from this population could give rise to clonal
mixed colonies of centrally located EpCAM?/CK19?
luminal cells surrounded by a halo of CK14? myoepithelial
cells and demonstrated bipotent progenitor activity. The
expression pattern of CALLA and MUC1 in the EpCAM?/
CD49f? population suggested this bipotent progenitor
might be located in the basal compartment, in contrast to
previous findings [47]. The discrepancy between these two
studies may reflect the addition of fibroblast feeder layers
the later study providing niche-derived signals that main-
tain the identity of these cells, as had been observed
previously in the mouse [30].
Similar results were obtained in the laboratories of
Eaves and Petersen. Like the studies above, markers for
EpCAM and CD49f were used to fractionate the lineage-
negative epithelium into a mammary stem cell population
(EpCAMlo/CD49fbright), lineage-restricted luminal progen-
itor (EpCAM?/CD49f?) and mature luminal (EpCAM?/
CD49f-) and myoepithelial lineages (EpCAM- to lo/
CD49f?) [50, 51]. Using these methodologies, human
stromal cells are characterized by an EpCAM- and CD49f-
negative immunophenotype and high expression for alde-
hyde dehydrogenase 1 (ALDH1) [52]. A human breast
luminal progenitor can also be identified from the lineage-/
EpCAM?/CD49f? fraction using the combinations of
luminal markers CD133 (referred to previously as Promi-
nin 1)/MUC1 and basal makers CD10/THY1 [53]. The
basally located MUC1-CD133-(CD10/THY1)? subset of
CD49f? cells contained the majority of the bipotent breast
colony-forming cells as assessed by their immune-pheno-
type in 2D colony-forming assays on collagen-coated
plates. The (MUC1/CD133)?CD10-THY1-/CD49f? con-
tained mostly luminally restricted progenitors.
Interestingly, progesterone receptor transcripts were enri-
ched in the bipotent progenitor population and not in the
luminal restricted progenitors, with the opposite pattern
observed for the estrogen receptor, suggesting that the
expression of these steroid hormones receptors is not
always overlapping. The corresponding populations in the
CD49f- population contained mature luminal cells devoid
of colony-forming ability. Hence, it was hypothesized that
the human breast was composed of undifferentiated bipo-
tent progenitor cells that give rise to committed progenitors
that differentiate into myoepithelial and luminal cellular
lineages and each cell can by purified based on the
expression of EpCAM/CD49f and additional luminal
(MUC1/CD133) and basal markers (CD10/THY1).
Parallel populations were obtained using a different
combination of cell surface markers in the mouse. In
studies from the laboratories of Eaves and Visvader, anti-
bodies for CD24 and the integrins CD49f (integrin alpha
6/VLA) and CD29 (b1 Integrin) were used in combination
and examined for their ability to fractionate the epithelium
into its cellular compartments. In these studies, mouse
lineage cells were depleted using antibodies against CD31?
(endothelial), CD45? (hematopoietic), TER119/Ly76?
(erythroid) and CD140a/Pdgfr alpha? (fibroblasts, ([4]
only) prior to fractionation. CD49f and CD29 had previ-
ously been identified as markers of stem cells in the mouse
epidermis [54–56]. Given that the mammary gland origi-
nates in the ectoderm [57] such as the epidermis, there may
indeed be an overlap in the expression of stem and pro-
genitor markers between these organs. Expression of CD24
and high expression of either CD29 or CD49f resolves a
population enriched for mammary repopulating units, i.e.
those that can give rise to complete mammary outgrowths
on transplantation. This population predominantly expres-
sed markers of basal/myoepithelial cells (CK14? and alpha
SMA), although the mammary repopulating units/stem
cells comprise only a small percentage of this population (1
mammary repopulating unit in 63-64 CD24?/CD29hi or
CD49fhi cells). Importantly, mammary outgrowths gener-
ated from limiting numbers of these mammary

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mammary cell hierarchy 4307
123
repopulating units could be serially passaged, thereby
demonstrating their self-renewal capacity. The actual fre-
quency of mammary stem cells may up to 5 % based on the
frequency of takes from single cell transplants (6 takes in
102 transplants [3] ); however, the question still remains
whether immuno-phenotype of mammary stem cells is
indeed that of predominant basal/myoepithelial population.
Interestingly, neither Sca-1 expression or Hoeschst 33342
and rhodamine 123 efflux properties were enriched in the
CD24?/CD29hi or CD49fhi cells, suggesting that the later
sorting strategies were superior to these earlier methods.
The CD24?/CD29lo or CD49flo population enriched a
population of luminal mammary epithelial cells that gave
rise to alveolar structures and expressed milk proteins
when placed into the 3D culture [3, 4, 58] providing evi-
dence for the existence of a more committed luminal
progenitor. Although the efficiency of mammary stem cells
to repopulate a mammary gland was significantly reduced
at limiting cell dosages [4], both studies provided the first
direct evidence that a single mammary stem cell, defined as
CD24?/CD29hi or CD49fhi, could be isolated by flow
cytometry and when transplanted could give rise to a
functional mammary gland. The existence of this stem cell
was demonstrated by Smith and colleagues, and here was
its first isolation. In contrast to the mouse mammary epi-
thelium, CD24 expression is confined to the luminal
compartment in the human breast, and highlights a critical
difference between the two species [53, 59]. Interestingly,
mammary cell-autonomous loss of CD24 and CD49f
resulted in no defects in mammary reconstitution capacity
suggesting that although these two proteins are able to
mark and enrich for mammary stem cells, they are not
required for mammary stem cell function [60, 61].
Although the markers that define the different populations
in the human and mouse vary (Table 1), similarities in the
transcriptomes of each population can be observed [62].
For example, the expression of the transcription factors
Twist2, Slug, Id4, p63 and Sox11, the Notch ligand Jag2
and WNT/b-catenin pathway members, Fzd8 and Tcf4 are
highly expressed in the mammary stem cell populations of
both species. In luminal progenitor cells high expression of
Elf5, cKIT, CYP24A1 and ALDH1a3 is observed, as is
true for Foxa1, Myb, ER, PR, Prlr, Tnfsf11 (Rank ligand)
in the mature luminal populations.
To further characterize the luminal populations, the
Visvader laboratory used an antibody for CD61 (Integrin
beta 3/GPIIIa), which defines the megakaryocytic cell
lineage. CD61 expression defines two overlapping popu-
lations in the CD24?/CD29lo luminal subset in the mouse
[5, 63]. This population is highly enriched for luminal
(CK18?) colony-forming cells that give rise to alveolar
structures in 3D culture, whereas the CD61- population
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(CK18) and was devoid of colony-forming ability. The
proportion of CD61? positive cells dramatically decreased
during pregnancy (decreasing 15-fold by 18 days post
coitus) consistent with increasing differentiation toward
mature alveolar cells characterized by a CD24?/CD29lo/
CD61- immuno-phenotype [5]. Hence, CD61 expression
in the CD24?/CD29lo defined a luminal progenitor
(CD61?) and mature luminal cells (CD61-). Later, the
Visvader laboratory demonstrated that the CD24?/CD29lo
population could be alternately fractionated into a cKIT?
progenitor population that likely overlaps with the previ-
ously identified CD24?/CD29lo/CD61? luminal progenitor
population [64]. cKIT/CD117 or receptor tyrosine kinase is
highly enriched in the luminal progenitors of both human
and mouse epithelium [62]. Furthermore, negative or low
expression of cKIT in the CD24?/CD29lo population that
also expressed CD14 (cKIT-/lo/CD14?) can further purify
the luminal fraction into an alveolar progenitor population
that expressed milk in the absence of a lactogenic stimulus,
and a mature luminal population (cKIT-/CD14-). More
recently, the activity of the MMTV promoter within
mammary epithelial cell populations was reported to dis-
tinguish a multipotent progenitor population from within
CD24?/CD29lo cells with alveoli-forming capacity, par-
ticularly in response to pregnancy, but without potential for
self-renewal by serial transplantation [65]. These progeni-
tors showed an ELF5 high phenotype, while the non-
alveoli forming progenitors showed a pattern of gene
expression indicative of the hormone-sensing lineage.
Multipotency was inferred from the formation of alveoli
and milk protein production, but also that p63? myoepi-
thelial cells were formed. Whether these cells are able to
make both myoepithelial and epithelial cells remains con-
troversial. If so, this may represent a new lineage of
alveolar-myoepithelial cells, in contrast to a separate ductal
myoepithelial cell lineage, which could also explain the
contrasting myoepithelial cell susceptibility to apoptosis
during involution, and their net-like, rather than sheath-
like, arrangement in alveoli and ducts, respectively.
The currently definitive work on progenitor cell phe-
notypes was published in 2012 by Shehata, Stingl and
colleagues [66]. Having distinguished luminal and basal
populations in Lin- cells from mouse mammary gland
using EpCAM and CD49f, they divided the luminal pop-
ulation into three subpopulations on the basis of Sca1 and
CD49b staining. High colony-forming frequency and low
multipotent stem cell activity were associated with high
CD49b expression, indicating this population comprised
progenitor cells with either some limited capacity for
dedifferentiation to stem cells, or with some incomplete
stem cell differentiation. High estrogen receptor expression
(ER) and expression of GATA3 and FoxA1 were found in
progenitors marked by high Sca1 staining, while low/no
ER expression but high Elf5 and Lmo4 expression, along
with expression of milk proteins such as Mfge8 and Lalba,
basal markers such as K5 and high ALDH activity were
found in the progenitor population with low Sca1 staining.
High ALDH activity has previously been shown to mark
human mammary stem cells [67] and here marks a ER?
luminal progenitor cell. Similarly, high ALDH activity
together with high expression of ERBB3 can purify lumi-
nal alveolar progenitor cells from the EpCAM?/CD49f?
luminal progenitor compartment isolated from human tis-
sue [66]. These results are supported by additional work in
human tissue showing that ALDH activity is in fact the
lowest in EpCAM-/lo/CD49f? mammary stem and bi-
lineage progenitors but is greatest in the EpCAM?/CD49f?
luminal progenitors, a point when mammary cells become
committed to the luminal lineage [68]. Thus, a clear pro-
genitor cell dichotomy exists with gene expression patterns
indicative of a determined cell fate, either as the founders
of the lineage acting as hormone-sensing cells in the case
of the ER/FoxA1/Gata3 progenitors (also called luminal or
ductal progenitors) or as founders of the milk-secreting cell
lineage in the case of the Elf5/Lalba/Mfge8 cells (also
called alveolar progenitors).
Lineage tracing to map cell fate decisions
The various markers discussed above enrich, but do not
purify, mammary stem and progenitors cell populations. It
is unclear how tissue disaggregation, niche removal and its
random replacement during transplantation alter stem and
progenitor cell phenotype and activity [19, 69, 70]. A
potential solution to these issues is to genetically mark the
stem and progenitor cells, and then chase the mark
throughout development, to define the cell lineage that the
target cells produce. The key to lineage tracing is the initial
accurate marking of the intended starting population,
especially when targeting populations other than multipo-
tent stem cells, to avoid the confusion caused by
the marking of off-target cells. These techniques, coupled
to high-resolution imaging have recently become a reality
[69, 71, 72] and the pioneers of these techniques have
discovered both the advantages and pitfalls of these tech-
niques. The gastric epithelium is a prime example [71, 73–
75]. These studies employed the Lgr5 promoter, identified
as a putative stem cell marker, to drive the marking allele, a
Tamoxifen-inducible Cre that activated a LoxP-flanked
Rosa26LacZ reporter. Lgr5? cells were restricted to the
base of the pylorus crypts, and lineage tracing revealed that
they were rapidly self-renewing cells that gave rise to
multiple gastric epithelial progeny throughout adulthood,
hence possessing all the qualities of a stem cell [73]. When
these cells were deleted, however, there was no effect and
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the crypts remained intact. This revealed the presence of a
second stem cell pool, marked by Bmi-1 expression and
label retention and located at the ?4 position, that pro-
duced the Lrg5? cells but which could also directly
produce the cells of the crypt. Therefore, there are two
types of stem cell in the intestine, and whether one or both
are stem cells remains controversial. A worrying aspect of
these experiments is that the tamoxifen used to mark the
Lrg5? cells caused the apoptotic death of these cells [76,
77], which enhanced the production of cell progeny from
Lrg5? cells. Apoptotic suppression by genetic overex-
pression of Bcl-2 or knockout of Chk2 caused enhanced
production of Bmi1 cells, pointing to an apoptotic artifact,
but using a background, that may have influenced the
observations made. A further lesson from the studies of the
intestinal crypt is the ability of cells to dedifferentiate to
become stem cells. Buczaki and colleagues [78] used a
version of label retention, where the CreA fragment of the
CRE recombinase was fused with Histone 2B. Induction
(using beta-naphthoflavone) in double transgenic mice that
express CreB from the Rosa26 locus and the histone 2B-
CreA fusion gene, caused the CreA fragment to be retained
on histones of cells that had not divided. Administration of
intravenous dimerizing agent resulted in heterodimeriza-
tion of CreA and CreB to form a functional recombinase,
which marked non-proliferative cells. These cells were
chased and shown to become differentiated Paneth cells,
but could revert to become stem cells following tissue
damage that repopulated the crypt. Thus, the definition of a
stem cell needs to be carefully considered. In solid tissues,
stemness may be an activity, rather than an entity, that is
available to many cells to meet the spatial constraints of
solid tissue regeneration. This may be a key difference to
the stem cells of the immune system, which have provided
the paradigm for the mammary stem cell hierarchy. As we
will see, the problems of tamoxifen deletion of stem cells
and injury-induced formation of stem cells have most
recently arisen in the interpretation of mammary lineage
tracing.
As discussed above, the earliest examples of lineage
tracing in the mammary gland were performed in the Smith
laboratory using MMTV integration [12], and the same
laboratory was later involved with the description of an
adjunct mammary epithelial cell population [79] that was
later termed ‘‘parity-induced’’ mammary epithelial cells
(PI-MECs) [80], but is actually better described as ‘‘parity-
labeled’’ or ‘‘parity-amplified’’ as they are present before
pregnancy [81]. The description of this population pio-
neered inducible lineage tracing in the mammary gland
[79]. Here, transgenic mice-expressing Cre recombinase
under control of the mammary (and pregnancy)-specific
promoter for whey acidic protein (WAP) was crossed with
mice ubiquitously expressing a floxed Rosa/LoxP/Stop/
LoxP/lacZ gene. Lineage marking was induced by preg-
nancy. Cre-mediated recombination resulted in the
permanent expression of b-galactosidase, detected as a blue
color after X-Gal staining. Not all marked alveolar cells
underwent apoptosis during involution, and up to 20 % of
cells remained marked in involuted parous glands, com-
pared to 1 % in nulliparous glands. Transplantation showed
that these cells could produce both ducts and alveoli. These
cells accumulated as the lactation-deficient phenotype in
Prlr heterozygote animals resolved with repeated preg-
nancy and they serve as the cell of origin for neu-induced
tumors [80]. Interestingly, although the vast majority of
these cells are restricted to the alveolar lineages, some cells
show multipotency, seen as myoepithelial cells staining for
both beta-galactosidase and smooth muscle actin [82], or
using a WAP-driven Cre-activated GFP reporter, as GFP?
cells staining for K14. GFP? cells were able to reproduce
entire mammary glands in 4 of 11 attempts following the
transplant of 104 cells, suggesting multipotency [83]. GFP?
cells were observed within the CD24?/CD49fhi population.
WAP is thought to be a milk protein and so is considered
to mark differentiated cells, however, WAP is a direct
transcriptional target of the ETS transcription factor Elf5
[84]. Thus, WAP-driven lineage tracing may be equivalent
to Elf5-driven lineage tracing, albeit at reduced efficiency.
We have hypothesized that Elf5 expression has two major
effects in the mammary gland [85, 86]. When it is first
expressed it causes stem cells to become alveolar progen-
itor cells [87, 88], therefore defining the progenitor cell
populations by inducing epithelial characteristics [89].
Further increases in Elf5 expression, in response to hor-
monal influences [88] force a fate decision within the
progenitors, to become the Elf5hi secretory population, or if
estrogen signaling dominates to become the Elf5lo ER?
hormone-sensing population. WAP-directed lineage trac-
ing has the potential to infrequently label some very early
progenitor cells, which may still possess multipotency, and
some ER? sensor cells, but most of the labeled cells will be
the progenitors of secretory cells and their mature progeny
that form the alveoli. Thus, the observations of PI-MECs
with multipotency, self-renewal and common long-lived
alveolar progenitor activity can be readily understood. The
relationship of PI-MECs to alveolar progenitors, the sensor
cell population and Elf5 expression has recently been
defined by the laboratory of Pietersen and colleagues [90].
Using the WAP–CRE approach to activate a floxed-stop-
Rosa26 YFP cassette they observed overwhelming labeling
of the ER- secretory alveolar lineage, with just 6 % of the
ER? hormone-sensing lineage showing labeling. As no
YFP? cells were observed in the basal compartment by
flow cytometry, or by immunofluorescence or co-staining
with SMA, Pietersen and colleagues speculate that trans-
plantation may be the cause of observations of PI-MECs
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contributing to the myoepithelial lineage, though in these
types of experiments labeling inefficiency may also be a
cause. Conclusions based on the failure to make an
observation must be made with caution. qPCR measure-
ment of Elf5 in flow-sorted populations from involuted
parous glands showed that alveolar progenitors expressed
Elf5 and that a subset of these progenitors were labeled
with YFP. The equivalent progenitor activity of labeled and
unlabeled progenitor populations was seen in the YFP
expression pattern during subsequent pregnancies, with
alveoli showing either near complete or no/low frequency
of labeling, indicating their clonal origin and functional
equivalence [90]. These results support the contention that
WAP-driven labeling reports Elf5 activity, though at well
less than 100 % efficiency, and marks long-lived alveolar
progenitors. Elf5-driven fate mapping was reported this
year using doxycycline-inducible activation of the confetti
reporter under the control of the proximal region of the
Elf5 promoter [91]. Only luminal cells were marked. These
cells were long lived and a number contributed to the
formation of the alveoli during pregnancy, seen as multi-
colored alveoli. Again the conclusions that were drawn
regarding the absence of labeling in the ducts and of
myoepithelial cells must be treated with caution given that
marking cannot be 100 % efficient.
Blanpain and colleagues [92] investigated the issue of
transplantation altering stem cell activity. They observed
that K14-driven and doxycycline-inducible marking of
fetal mammary cells during late pregnancy labeled both
epithelial and myoepithelial cells, but that the same pro-
cedure immediately postpartum, or during puberty or
pregnancy, only labeled myoepithelial cells. A K5-driven
and tamoxifen-inducible system reproduced this result
[92]. Using luminal drivers such as K8 and K18, and
tamoxifen induction, only labeled epithelial cells were
observed. When K14-driven and doxycycline-induced
labeling of cells was performed in a 4-week-old mice, then
enzymatically disaggregated and transplanted, the myoep-
ithelial restriction was broken and both luminal and
myoepithelial cells were labeled. Recombination trans-
plantation experiments using these marked myoepithelial
cells mixed with increasing ratios of unmarked luminal
epithelial cells showed that the presence of luminal epi-
thelial cells inhibited the multipotency of the myoepithelial
stem cells. Thus, the conclusion drawn was that the epi-
thelial and myoepithelial lineages share a common stem
cell in utero, but from birth the gland is maintained by
unipotent stem cells that are restricted to the epithelial and
myoepithelial lineages. Postpartum multipotent stem cell
activity is either revealed, or produced, by transplantation.
Physiologically, the multipotent stem cell may be very
important for recovery from injury, such as mastitis, which
has a very high incidence in mammals during lactation.
Parallels between these unipotent stem cells (or are they
better called progenitor cells?) can be drawn with the
luminal- and myoepithelial-derived progenitors discovered
in earlier studies using markers of luminal cells (MFGM/
MAM-6/EpCAM) and myoepithelial cells (JB6/CALLA/
CK14), respectively [27, 28, 31, 32]. Whether these pro-
genitors represent the same cellular populations remains to
be determined.
Since the publication of this work by Blanpain and
colleagues, a number of papers have supported or ques-
tioned its conclusions. van Amerongen and colleagues [93]
used Axin2-driven and tamoxifen-inducible lineage tracing
of Wnt-responsive cells. When mammary cells were
labeled during the fetal period, marked cells were restricted
to the luminal fate with no marked basal cells observed by
flow cytometry. Labeling postpartum produced the oppo-
site result, labeling of basal not luminal cells. When these
cells were transplanted both luminal and basal layers of the
ductal tree were produced, and alveoli were now derived
from cells previously marked as basal. This pattern of
marking was transplantable and suggests activation of
multipotent stem cell activity by transplantation. Post-
pubertal animals continued to show a basal pattern of
labeling. During pregnancy this pattern persisted, but
newly formed alveoli showed labeled cells that produced
milk at the end of pregnancy. After multiple pregnancies
and involutions, this labeling pattern persisted in the ducts
and regressing alveoli. These findings, which are compat-
ible with the Blanpain model, show that Wnt activity
occurs in both the basal and luminal progenitor compart-
ments, but whether one becomes the other, as would occur
in a multipotent stem cell model, will require labeling with
confetti [94] or brainbow [72] to demonstrate clear clonal
decent. The ability of the mammary fat pad to influence a
mammary-like differentiation fate is well known [95, 96],
so there is precedent for mammary cells being so
influenced.
Visvader, Lindeman and colleagues [91] have used K5-
driven doxycycline-inducible linage tracing to demonstrate
that multipotent stem cells do operate during normal
development and are not simply a product of transplanta-
tion. The use of confetti mice allows the stochastic
production of multiple colors, allowing the simultaneous
observation of multiple clones within the same region of
mammary architecture [94]. Using this model in adult
mice, they observed labeled cells in both luminal and
myoepithelial lineages, and these cells contributed to
alveolar morphogenesis. A K14-driven and tamoxifen-
activated model, and a Lrg5-driven tamoxifen-activated
model produced the same result-labeled cells in both
myoepithelial, luminal and alveolar cells, consistent with
the activity of a multipotent stem cell during normal
mammary development. The disparity between this study
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and the previous studies is stark. Possible reasons include
model differences in promoter specificity and/or tran-
scriptional activity due to transgene insertion sites or the
different promoter fragments utilized, producing labeling
in different cell lineages and with different efficiencies.
The use of 2D rather than 3D confocal imaging is another
difference. The ability of high doses of tamoxifen to kill
mammary stem cells offers another distinction; however,
doxycycline is not thought to cause this problem (as yet),
and many of the divergent results were produced using
doxycycline, not tamoxifen to induce labeling. Drawing on
the lessons learned from the mapping of the cellular hier-
archy of the intestinal epithelium, where fast and slow stem
cells operate, and phenotypic plasticity occurs, the resolu-
tion of these disparate observations is likely to be in the
undiscovered complexities of the mammary hierarchy.
Lgr5?, a marker of pyloric stem cells, has also been
used to trace mammary cell lineages [97]. Just 5 % of
the CD24mid/CD49hi mammary stem cell-enriched popu-
lation expresses Lgr5. Interestingly, lineage tracing of
Lgr5? cells from the first day after birth resulted in
labeling of the luminal progenitor cell compartment only,
and only when cells were traced from the twelfth day of
birth did Lgr5? cells label the myoepithelial compart-
ment. The switching in the Lgr5? progenitor cell activity
may reflect changes in Wnt signals from the microen-
vironment at different developmental stages. Importantly,
these results add further evidence that distinct mammary
progenitors have discrete roles at various stages of
development.
There may be several new progenitor cells that are yet
to be revealed. Fascinating evidence for this comes from
the study of Sale and colleagues who traced Notch2
expression [98]. Small Notch2-expressing cells formed
rings around a large Notch2 cell, and these colonies
occurred in a repetitive and equally spaced arrangement
within the terminal end bud and the trailing duct, where
the pattern persisted post-pubertally. Large Notch2? cells
appeared with random frequency throughout the duct. All
Notch2? cells expressed keratin 8 and not keratin 14
showing them to be exclusively epithelial. They fall
within the CD24?CD29low population and many are also
CD61? suggesting there are potential progenitor cells
among them. Transplantation showed no outgrowths
from these populations and lineage tracing showed no
clonal alveolar development, indicating that these cells
are not classical progenitors. Small cell strings were
localized at tertiary branch points, and forcing the
expression of the diphtheria toxin receptor under Notch2
control resulted in the cessation of branching when
diphtheria toxin was administered mid-puberty. At
pregnancy, diphtheria toxin prevented correct alveolar
morphogenesis, resulting in poorly organized hyperplastic
regions where alveoli should have formed, and little milk
protein synthesis. These cells show morphologic simi-
larity to the small light cells and large light cells
previously identified using ultra-structural microscopy in
the Smith laboratory [20]. The source of these cells
remains unknown. Regardless, it is clear that the lineages
within the mammary gland are far more complex than
currently realized.
Lineage tracing studies have therefore identified new
progenitor subtypes that have discrete roles in a stage-
dependent context. Importantly, these techniques have
revealed key differences in the lineage potential of mam-
mary stem and progenitors in unperturbed glands in vivo
compared to those where these populations have been
isolated by flow cytometry and examined in mammary
reconstitution assays. The extent of the overlap between
these new progenitor subtypes and those identified in early
morphological and prospective isolation studies remains to
be determined. The advent of superior lineage tracing
techniques, for example those that employ Brainbow or
Confetti transgenic mice [72, 94], paves the way for a more
advanced understanding of the mammary cellular hierar-
chy. The challenge now is choosing appropriate genes to
drive lineage marking. The best genes for this purpose are
those that define the various lineages within the mammary
gland.
Regulation of the mammary cellular hierarchy
The Smalley laboratory showed that a hormone-sensing
population exists separately from stem cell activity [43].
It is widely accepted that steroid receptor expression
segregates from proliferating cells, and that paracrine
signals from steroid receptor-positive cells must con-
tribute to the proliferation of adjacent hormone receptor-
negative cells [44, 45, 99]. The mammary stem cell-
enriched population is likely negative for the expression
of steroid hormone receptors, so the question remains,
how do steroid hormones regulate the proliferation and
self-renewal abilities of mammary stem cells? That ste-
roids do influence stem cells was demonstrated by the
Khokha and Visvader laboratories [6, 100]. At diestrous,
when progesterone levels are highest, the absolute
numbers of CD24?/CD49fhi mammary repopulating units
in the mammary gland increase by up to 14-fold over
that observed at estrous [100]. Furthermore, the size and
repopulating capacity of the CD24?/CD29hi mammary
stem cell population decreased in ovariectomised mice
and increased in mice treated with estrogen [6] and
progesterone [6, 100]. Three weeks of treatment with the
aromatase inhibitor Letrozole, which inhibits the syn-
thesis of estrogen, is sufficient to significantly decrease
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the numbers and activity of mammary stem cells [6].
These results suggested that a paracrine mediator is
responsible for the proliferation and maintenance of
mammary stem cells, and a likely candidate was the
progesterone-regulated RankL [100]. In fact, it is now
understood that PR has two modes of mitogenic action
in the mammary gland; firstly a cyclin D1-dependent
stimulation of proliferation of PR? cells, and secondly a
RankL-mediated paracrine action on nearby PR- mam-
mary epithelial cells [101]. Indeed, treatment of mice
with a RankL-neutralizing antibody decreased both the
numbers and the colony-forming ability of CD24?/
CD29hi mammary stem cell-enriched population [6].
Hence, mammary stem cell maintenance likely occurs
via paracrine signals that include RankL, which is
released from neighboring steroid receptor-positive cells
where it is induced by steroid hormones. RankL activi-
ties are not confined to the mammary stem cell
compartment as RankL can also stimulate the expression
of the transcription factor Elf5 in progesterone receptor-
negative luminal progenitor cells and promote alveolar
development [88]. In these experiments, progesterone
treatment of mice alone resulted in an expansion of the
CD24?/CD29hi mammary stem cell-enriched compart-
ment, confirming progesterone driven action on
mammary stem cells. Progesterone also resulted in
a depletion of the CD24?/CD29lo/CD61? luminal pro-
genitor cell population and drove its differentiation
toward the CD24?/CD29lo/CD61- mature luminal cell.
Forced expression of Elf5 in the luminal compartment,
together with progesterone treatment, completely deple-
ted the luminal progenitor population and resulted in the
expansion of the mature alveolar lineage. RankL-neu-
tralizing antibody blocked the action of progesterone in
this model and suggested that most of the action of
progesterone on luminal cell differentiation is dependent
on RankL paracrine signaling. Forced Elf5 expression
also reduced stem cell numbers, suggesting an action of
Elf5 to differentiate these cells. Hence, both mammary
stem and luminal cells are regulated by paracrine signals
from committed steroid receptor-positive luminal cells.
Paracrine signals from basal epithelial populations
may also control the proliferation and fate of the luminal
epithelium. Forster and colleagues provide evidence for
this. Genetic deletion of the transcription factor p63 in
K14-positive basal epithelium resulted in profound
defects luminal cell proliferation and differentiation
during pregnancy [102]. No changes in basal cell number
or proportion were detected; however, the proportion of
luminal progenitors (CD24?/CD29lo/CD61?) accumu-
lated in the mammary glands of mice, suggesting that
they had failed to differentiate into mature alveolar cells.
These p63-competent luminal epithelial cells could be
made to differentiate into large alveolar-like colonies
when cultured in complete medium suggesting that a
p63-dependent paracrine factor released from basal cells
may be responsible for their fate. This factor was found
to be neuregulin (Nrg1, heregulin-alpha), produced by
the basal epithelia, and found to be a direct transcrip-
tional target of p63. Exogenous Nrg1 rescued the
lactation phenotype in recombined glands with basal cell
p63 deletion, and this occurred through activation of the
ERBB4/Stat5A in neighboring luminal epithelial cells
[102]. Hence, in addition to paracrine signals that travel
from luminal sensor population to other luminal cells
and basally located mammary stem cells, basal cells
themselves can send signals back to regulate the fate of
the luminal epithelium. This ‘teamwork’ likely underlies
every aspect of breast development and homeostasis and
is only beginning to be unraveled [103].
Transcription factors govern large genomic networks
and regulate cell fate specification within the mammary
cellular hierarchy. For example, the expression of the
transcription factor Gata3 is highly enriched in the
CD24?/CD29lo/CD61- mature populations and mam-
mary specific loss of this transcription factor resulted in
at least a twofold increase in the size of this population,
whether isolated from a virgin gland or during preg-
nancy. Furthermore, forced expression of Gata3 in the
CD24?/CD29hi mammary stem cell-enriched population
resulted in the expression of markers of luminal cell
differentiation and milk proteins. These results suggested
that Gata3 is essential for luminal cell fate specification
at multiple stages of the mammary cellular hierarchy [5].
The fate of the CD24?/CD29lo/CD61? luminal progeni-
tor is also driven by the Ets transcription factor Elf5.
Mammary specific loss of Elf5 results in complete fail-
ure of alveolar morphogenesis and milk secretion [8].
Conversely, forced expression of mammary specific Elf5
results in precocious alveolar differentiation of virgin
epithelium and milk production together suggesting that
Elf5 is the master regulator of alveolar morphogenesis. A
greater proportion of the CD24?/CD29lo/CD61? luminal
progenitor population is observed in Elf5 knockout
mammary glands and the converse was true in transgenic
animals expressing Elf5, where forced expression of Elf5
eroded the CD24?/CD29lo/CD61? luminal progenitor
and specified its differentiation along the alveolar cell
lineage. It is likely that Elf5 expression is a key deter-
minant in the differentiation of stem cells to progenitor
cells, via its epithelializing influence [86, 87], which
distinguishes the myoepithelial and epithelial lineages
and correlates with the loss of epigenetic silencing of
Elf5 in epithelial cells, but not the stem and myoepi-
thelial compartments. Elf5 is then also involved in the
determination of the two progenitor lineages via a
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Fig. 1 The stem cell niche during mammary development and
carcinogenesis. a Traditional view of the mammary hierarchy: a
mammary stem cell resides at the top of the hierarchy, present in the
embryonic mammary gland and possibly in the adult. It gives rise to
committed bipotent progenitor cells, which under the influence of
extracellular and intracellular cues give rise to progenitors and mature
cells in their respective lineages. b The mammary hierarchy exists
within a cellular niche that has different activities, and locations, with
each developmental stage. c The activity of the niche is disrupted
during carcinogenesis, the exact nature of which may produce the
heterogeneous cancer subtypes observed
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mutual negative regulatory loop involving ER and
FoxA1, so that one or the other phenotype is fixed by
dominant transcriptional repression of the other [85, 86,
104].
The NOTCH signaling pathway has also been shown to
play a role in lineage specification in the mammary gland.
The Notch pathway involves juxtacrine signaling between
cells in direct contact with each other via the Notch
transmembrane ligands (Delta-like DLL1, 3, 4 and Jagged
Jag1–2) of one cell and the Notch transmembrane receptors
(Notch 1–4) on a neighboring cell [105]. The cleaved
intracellular domains of the Notch receptors (NICD)
translocate to the nucleus where they also activate pro-
grams of transcription. The Notch active intracellular
domain is released by gamma secretase cleavage permit-
ting its translocation to the nucleus where it interacts with
the CSL complex to activate the transcription of target
genes that include Hes and Hey. The expression of Notch
ligands, receptors and transcriptional targets is differen-
tially regulated in mammary stem, luminal progenitor and
mature luminal enriched populations [106]. Interestingly,
Notch4 was first discovered as an integration site for
MMTV, previously termed Int3, which resulted in the
constitutive expression of a cleaved form of Int3/NICD4,
which drives the formation of mammary tumors [107, 108].
The expression of NOTCH1-signaling components is
greatest in the luminal lineages, and forced expression of
the active NICD1 in CD24?/CD29hi mammary stem cell-
enriched population directs this population towards the
luminal cell lineage [106]. Conversely, knockdown of
CBF-1, a target of NICD1 resulted in expansion and
increased repopulating capacity of the mammary stem cell-
enriched population. The effects of Notch in mammary
stem cells are likely mediated at least in part via signals
from Elf5 [87]. Interestingly, forced Notch signaling in
luminal progenitor cells resulted in an expansion of this
compartment and the formation of luminal (CK8?/CK18?/
E-cadherin?/SMA-/p63-) hyperplastic alveolar nodules
when transplanted into de-epithelialized mammary glands
[106]. Similar regulation of human breast stem and pro-
genitor cells is apparent in the human breast [109]. Further,
inappropriate expression of Notch results in transformation
of luminal progenitor cells. These data demonstrate that
Notch is essential for restricting the expansion of mam-
mary stem cells and for driving luminal cell commitment.
Recent evidence suggests a number of additional sig-
naling pathways and transcription factors can regulate
specific aspects of the mammary cellular specification [7,
9]. Hence, lineage specification and homeostasis of mam-
mary stem and progenitor cells is governed by interactions
among steroid hormone-signaling paths, lineage-specific
transcription factors and signals derived from the extra-
cellular niche.
Stem cells in cancer
Substantial evidence confirms the existence of cancer stem
cells in several tissues. The existence of cancer stem cells
was demonstrated in human leukemia, where limiting
dilution xenotransplantation of CD34?/CD38- leukemic
cells recapitulated the entire original tumor, whereas
CD34?/CD38? and CD34- leukemic cells were not
tumorigenic at any cellular concentration [110, 111].
Subsequent studies demonstrated that the tumorigenic
potential was not restricted to these markers as human
CD34?/CD38? leukemia cells also produced tumors in
mice [112–115]. In an attempt to isolate and understand
tumorigenic from non-tumorigenic breast cancer cells, Al-
Hajj and colleagues [40] used antibodies against CD24
(Heat stable antigen/HAS/BA-1) and CD44 (H-CAM/Pgp-
1) to separate heterogeneous cell types in patient-derived
xenografts grown in immune-compromised mice. These
cell surface receptors bind cell adhesion molecules on
neural stem cells and melanoma cells [116, 117]. Cells
derived from leukocytes, endothelial cells, mesothelial
cells, and fibroblasts were eliminated using the lineage
markers CD2, CD3, CD10, CD16, CD18, CD31, CD64,
and CD140b [40]. Lineage cells that were positive for
CD44 and had no or low expression of CD24 (CD44?/
CD24-/lo) were enriched for tumorigenic activity [40]. In
contrast, CD24? contained differentiated tumor cells that
failed to form tumors. Further enrichment of tumorigenic
cells was achieved with additional staining using an anti-
body to ESA or EpCAM. Importantly, ESA?/CD44?/
CD24-/lo cells isolated from patient xenografts in mice
could give rise to the complete cellular heterogeneity
observed in the primary tumor in serially passaged xeno-
grafts, hence lineage-/ESA?/CD44?/CD24-/lo tumorigenic
cells were self-renewing and multipotent cancer stem cells
[40]. Whether these tumorigenic cells represent the cellular
origins of breast cancers remains to be determined.
Since these experiments, an understanding of cancer
stem cells has evolved rapidly [118–123]. The CD44?/
CD24lo definition has also been found to enrich for cancer
stem cells in the Her2/Neu mammary tumor mouse model
[124]. Similar to observations of cancer stem cell pheno-
types in hematopoietic malignancies, CD44?/CD24lo is not
a universal marker of cancer stem cells in breast cancer.
Furthermore, differences in the oncogenic mutations that
drive transformation have profound effects on the fre-
quency and phenotype of cancer stem cells. This is true for
mouse models of mammary cancer. The CD24?/CD29lo/
CD61? immuno-phenotype enriched a population of can-
cer stem cells in Wnt1-driven tumors, and in part in tumors
that develop in p53 heterozygote mice, but not in tumors
driven by overexpression of Her2/Neu [125]. Although
these studies clearly demonstrate the existence of small
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population of cancer stem cells, like the situation in normal
mammary gland, no markers have been found to reliably
define cancer stem cells in mammary cancers.
The progenitor cell as the major origin of breast cancer
Stem cells could serve as the cell of origin of cancer as they
are self-renewing, long-lived and hence likely to accumu-
late mutations over time [126–128]. Efforts have been made
to match the intrinsic molecular subtypes of breast cancer
with distinct cancer stem cells. Tumors could arise from
committed progenitor cells, with enough residual multipo-
tent potential to give rise tumor cellular heterogeneity,
comprised of lineage-committed tumor cells and small
proportions of tumor-initiating cells. Stem cells may
acquire the first genetic aberration and give rise to progeny
that is predisposed to further mutations, triggering the onset
of the disease [119]. Tumors display a dichotomy of hor-
mone-responsive and non-responsive cells, where
expression of ER and PR is variable within each intrinsic
molecular subtype [128]. This dichotomy resembles that
observed in the normal mammary gland. Whether tumors
arise from transformed mammary stem cells that acquire
heterogeneity through clonal evolution, or whether cancer
arises from committed progenitor(s) or transit-amplifying
cells is still unclear. It is more likely that both mechanisms
coexist with different incidence in distinct breast cancer
subtypes.
Research in hematopoietic malignancies provides evi-
dence that committed progenitors cells may serve as cells
of origin for malignancy [129]. Similar results have been
shown for breast cancers [52, 119, 130] as was demon-
strated by Molyneux et al. in 2010 [131]. In this study
deletion of Brca1 in Blg (b-lactoglobulin)-positive luminal
progenitors from p53?/- mice produced ER-basal tumors
that phenocopied Brca1 mutant tumors, whereas depletion
of Brca1 in the CK14? basal progenitor produced basal-
like breast cancers that did not resemble those found in
human patients, suggesting that Brca1 tumors likely arise
from a luminal progenitor. This work is supported by the
result that the luminal population is larger in Brca1
mutation carriers and possesses growth factor-independent
growth properties [52]. Similarly, constitutive activation of
the Notch1 pathway in luminal progenitors resulted in their
transformation and resulted in hyperplasias with luminal
characteristics [106]. Transformed committed progenitor
cells may also dedifferentiate and acquire stem cell-like
properties. A model for committed progenitors that acquire
stem cell properties during regeneration/wound-healing
responses has being described for prostate testis and pan-
creas [51, 132, 133]. These data support the notion that
malignancy may originate in the progenitor cell
compartment and result in the establishment of heteroge-
neous subtypes of breast cancer.
Following this hypothesis, factors which determine the
cell fate decisions of the normal progenitor cell are likely
to be key determinants of tumor phenotype, response to
therapy and molecular subtype. Thus, transcription factors
that specify normal mammary cell fate, such as Elf5 or
Gata3, also have a profound effect on tumor progression
[64, 86, 89, 134, 135] and therapeutic resistance [86]. For
example, forced expression of Elf5 in ER-positive luminal
breast cancer cells reduced ER and FOXA1 expression and
suppressed the luminal subtype molecular signature [86].
Knockdown of Elf5 in basal breast cancer cells also
resulted in a shift in their molecular signature toward a
claudin-low and normal-like subtype of breast cancer
suggesting that Elf5 is a key determinant of breast cancer
intrinsic molecular subtype. Elf5 expression is greatly
increased when MCF-7 breast cancer cells acquire
Tamoxifen or Faslodex resistance by long-term exposure to
these anti-estrogens, and these cells also become dependent
on Elf5 for their proliferation, suggesting that Elf5 is a key
determinant for anti-estrogen resistance [86].
Additional sources of breast cancer heterogeneity
In addition to the cell of origin, many other factors con-
tribute to the observed molecular tumor heterogeneity
[136–139]. Transcription factors figure prominently in the
differential signatures [64, 85, 86, 140, 141]. Tumors
exhibit marked morphological heterogeneity [127, 142].
Clonal evolution of tumors could result in tumor hetero-
geneity [143] via the acquisition of advantageous
mutations that confer survival advantages [126]. Further-
more, heterogeneity may arise in response to the tumor cell
microenvironment, where for example, tumor cells directly
in contact with blood vessels are different from those in an
anaerobic environment far from the vasculature [144]. The
effect of the microenvironment is a critical source of tumor
heterogeneity [126, 145, 146]. The suggestion that mam-
mary stem cells are located in a ‘suprabasal’ niche within
the mammary gland [22, 32, 47, 48, 147], imply that such
cells will be poised to respond to extracellular cues that
regulate their fate [148]. There are examples in multiple
tissues suggesting that the niche provides signals to
maintain the self-renewal capacity of stem cells and upon
exiting of this niche, stem cells undergo differentiation
[149]. The existence of a stem cell niche [150], and the
effect of hormones and paracrine factors on mammary stem
cells during mammary gland development [88, 151–153],
may similarly affect cancer stem cells resident in breast
tumors. Furthermore, tumors contain more than tumor
cells; for example, endothelial cells, immune-infiltrated
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populations and fibroblasts. Each cell type plays an
important role during the initiation and progression of the
disease [154–156]. Epigenetics have been shown to play a
strong role during development [157] including mammary
development [104, 158], defining different lineages and
specifying epithelial functions. Therefore, it is reasonable
to think, epigenetic remodeling is similarly crucial for the
definition of tumor populations as a mechanism to define
committed decisions [159–161]. Together with genomic
instability, the underlying epigenetic mechanisms of nor-
mal mammary morphogenesis must be considered as a key
factor that contributes to tumor heterogeneity [162] as
many types of cancer retain certain a hierarchal organiza-
tion. In mouse models of mammary cancer, distinct
oncogenic insults produce different cancers supporting the
importance of the genetic mutation for the generation
of heterogeneous tumor phenotypes. [125, 163, 164].
Implications for therapy
Cancer stem cells provide an attractive target for the
development of novel cancer therapies and are likely
arbiters of the failure of anticancer therapies and relapse
[165]. Furthermore, cancer stem cells are considered to be
intrinsically resistant to chemotherapy [162] and radiation
[166]. Endocrine therapies, such as tamoxifen and aroma-
tase inhibitors for ER? disease or herceptin, have proven
efficacious [167], but may only target the ER? and HER2-
overexpressing mature tumor cell types and not multipotent
undifferentiated cancer stem cells [128]. These thera-
pies may also target the tumor microenvironment and
indirectly affect tumor cell interactions with the cancer
stem cell [168]. For example, it has been demonstrated that
a mechanism of action of trastuzumab is to attract immune
cells to the tumor site generating antibody-dependent cel-
lular cytotoxicity [169, 170].
New treatments have been developed that have been
designed to target cancer stem cells. An 11-gene stem cell
signature based on the Bmi-1 renewal pathway can predict
poor prognosis in multiple types of cancer including breast
cancer [171]. New therapies include those that induce
lineage maturation of cancer stem cells. Such a therapy has
been used in acute promyelocytic leukemia [172] or glio-
blastoma [173], producing growth arrest in tumor cells by
forcing their terminal differentiation. The rational behind
this type of therapy is not only to overcome intrinsic cancer
stem cell resistance and sensitize them to conventional
therapy, but also to prevent tumor cell dissemination. This
is because it has been suggested that although differenti-
ated tumor cells are able to seed in distant organs, only the
cancer stem cell will produce clinically relevant macrom-
etastasis [162, 174].
Conclusions and Perspectives
The mammary cellular hierarchy exists as a dynamic state
and which is intrinsically plastic (Fig. 1, cell types from the
seminal publication of Chepko and Smith [20]). The mul-
tipotent stem cell is thought to sit within a controlling
niche, where is poised to respond to exogenous cues and
signals from the niche microenvironment, to give rise to
more lineage-restricted oligopotent stem cells during post-
natal development. We know very little about the nature of
the niche, from its composition to the way it may control
mammary stem cell function, and these aspects are among
the key unanswered questions of mammary biology. We
can infer a little more regarding its location. During
embryogenesis, the mammary placodes form and invade
the underlying mesenchyme, to form the rudimentary
ductal network found at birth [176]. Within the placode,
the initial niche architecture is presumably laid down, with
the leading edge of invasion carrying a niche into the
mesenchyme. During ductal elongation, the niche repro-
duces itself while also depositing copies along the length of
the duct. Puberty activates the multipotent stem cells at the
ductal termini, which may divide in specific directions, so
that division along the plane of ductal elongation produces
myoepithelial-committed oligopotent stem cells in the
forward direction and luminal-committed oligopotent stem
cells in the reverse direction. In turn, these stem cells
produce the two major cell lineages of the mammary epi-
thelium, with terminal end bud cap cells, derived from
forward stem cell divisions, becoming the myoepithelial
layer, and the terminal end bud body cells, derived from
reverse divisions of the stem cell differentiating to become
the luminal lineages. If the stem cells divide in a direction
across the niche they may reproduce themselves, and so
seed the mammary epithelium with multipotent stem cells
as the terminal end bud advances. As ductal elongation
proceeds, the niche bifurcates to produce the characteristic
‘‘Y’’-shaped branch points. These myoepithelial and epi-
thelial niches deposited along the duct must cooperate to
produce ductal side branching, recognized as ‘‘T’’-shaped
branch points, in response to estrous/menstrual cycles and
pregnancy [182, 183]. Alternatively, there may be only one
type of niche and stem cell, which is able to vary the type of
cells it produces depending on context. Transplantation, or
the conditions of initial mammary development postpartum
or at puberty cause it to act as a mutipotent stem cell in
response to wound-healing stimuli, while lineage tracing
in vivo shows it to behave as an oligopotent stem cell with
more restricted epithelial or myoepithelial commit-
ment [91, 92]. Non-Waddington stem/progenitor cell
dedifferentiation and transdifferentiation should also be
considered as a response to disruption of the niche. How the
niche may contribute to cancer heterogeneity is also a key
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question. Currently, it appears that the luminal progenitor is
the basis of most breast cancers, comprised of luminal and
basal subtypes (Fig. 1) with the stem cells producing much
rarer mesenchymal subtypes such as the claudin-low can-
cers. Additional progenitor lineages may yet be discovered,
say for example one driven by progesterone that may
account for the luminal B type of cancers [175]. If the stem
cell is the target of oncogenic change, and the niche retains
its responses to external stimuli, then a wide variety of
tumor phenotypes could be produced from the same core
group of cells, with the niche replicating itself within the
tumor and its metastases. New technologies such as lineage
tracing, single cell whole genome analysis and our rapidly
evolving understanding of epigenetic control make this an
exciting time in mammary biology.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
Appendix: Mammary gland morphology
and development
The mature mammary gland is composed of a bi-layered
epithelium consisting of luminal cells that give rise to the
milk-secreting alveoli during pregnancy, surrounded by
contractile myoepithelial cells that contribute to milk
ejection during lactation. These layers of epithelium are in
close proximity to the extracellular matrix (ECM) and sit in
a bed of stroma consisting of adipocytes and fibroblasts,
and infiltrated with the blood and lymph vasculature.
Macroscopically, mouse mammary epithelium forms
a complex network of ducts terminating in alveolar buds
connected to the nipple by a single canalized duct. In the
human, terminal ductal lobular units cap the ends of the
ducts and are made up ductules and alveolar buds.
Reproductive hormones from the endocrine system, toge-
ther with secreted factors from epithelial cells and the
extracellular matrix, drive cell fate and functional differ-
entiation within the mammary epithelium in a spatial and
temporal manner during all stages of mammary
development.
Mammary gland or breast morphogenesis occurs lar-
gely after birth from a rudimentary ductal tree that forms
during embryogenesis (Fig. 2). Mammary embryonic
development gland is initiated at embryonic day 10–11 in
the mouse and at 4 weeks in the human [57, 176], where
primordial mammary buds emerge from thickenings of
the ectoderm (placodes) along the milk line that forms
primitive mammary buds and at birth the rudimentary
ductal tree [176, 177]. Each duct is capped with terminal
end buds which are composed of an outer layer of
undifferentiated cap cells, inner layers of highly prolif-
erative luminal epithelial cells and an apoptotic plate
behind the luminal cells resulting in ductal canalization
[178]. The rudimentary mammary epithelium enlarges
isometrically until puberty, largely under the influence of
growth hormone and estrogen [179–181].
Pituitary gonadotropins trigger the onset of puberty
[182] and mammary ductal branching morphogenesis in
response to oscillating levels of estrogen and progester-
one during the estrous cycle [183, 184]. The cyclical
surges of ovarian hormones post-puberty result in con-
tinuous rounds of proliferation and incomplete apoptosis,
and result in the establishment of a complex network of
ducts that penetrate to the extremities of the fat pad
[185–188].
Pregnancy triggers alveolar morphogenesis and is under
systemic control of luteal progesterone, pituitary prolactin
and later placental lactogen. The mammary epithelium
undergoes rapid proliferation resulting in increased
branching and the development of the alveolar epithelium,
which terminally differentiates into the alveolar epithelium
capable of milk secretion at mid-pregnancy [189, 190]. At
weaning, this newly formed alveolar epithelium regresses
via apoptosis leaving the ductal epithelium largely as it was
prior to pregnancy [191], although it is now recognized that
some parity-induced mammary epithelial cells remain [79,
82] concomitant with permanent changes gene and protein
expression [192].
bFig. 2 Mammary gland development, embryonic to pregnancy and
beyond. a The mammary gland emerges from mammary placodes that
form along the milk line at embryonic day 10–11. At birth, the
mammary epithelium emerges from the placode and grows isomet-
rically until puberty when rapid expansion of the epithelium extends
the ducts throughout the fat pad. Ductal side branches sprout from the
lateral surfaces of the ducts in multiple rounds of proliferation
throughout each estrous cycle and results with the complete filling of
the mammary fat pad. This process is collectively termed ductal
morphogenesis. Pregnancy induces alveolar morphogenesis where
proliferation establishes the alveolar epithelium, which then differ-
entiates into milk-secreting alveoli at mid-pregnancy (lactogenesis
I/secretory initiation). The final phase of differentiation results in milk
and lipid movement into the alveolar lumens ready for lactation
(Lactogenesis II/secretory activation). Milk ejection maintains lacta-
tion, and after weaning the mammary gland undergoes rapid
programmed cell death (involution), returning the gland to a near-
virgin state. b Mammary whole mounts (Carmine alum stain top row)
and mammary cellular architecture (hematoxylin and eosin histology
bottom row) in virgin, 6 days post coitus (dpc), 12 dpc, 18 dpc and
1-day postpartum (1dpp) murine mammary glands. Ductal epithelial
cells (arrow), myoepithelial cells (arrowhead) and adipocytes (A) are
indicated. Alveoli form a sphere-like single layer of epithelial cells
enveloping a circular lumen (X) and contain cytoplasmic lipid
droplets from 18 days post coitus, after secretory initiation (asterisk).
At parturition, tight junctions between alveolar cells close and milk
proteins and lipid are secreted into the alveolar lumen (X). An
expansion of the vasculature (open arrows) and reduction in area is
also apparent in the stroma
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